Early observations and pilot data that first suggested a new direction
Immune thrombocytopenia (ITP) was managed for decades with a limited toolkit: corticosteroids as first-line, followed by splenectomy for refractory cases. While splenectomy achieved durable remission in approximately 60-70% of patients, it carried operative risks and long-term infection susceptibility. Intravenous immunoglobulin (IVIG) and anti-D provided temporary platelet boosts. The landscape began shifting when rituximab, an anti-CD20 monoclonal antibody developed for lymphoma, showed unexpected efficacy in ITP by depleting autoreactive B cells. Early case series by Stasi et al. and others demonstrated initial response rates of 40-60%, sparking interest in targeted immunological approaches.
Landmark RCTs and pivotal trials that established the evidence base
The development of thrombopoietin receptor agonists (TPO-RAs) transformed ITP management. Romiplostim (AMG 531), a peptibody mimicking thrombopoietin, was evaluated in two pivotal RCTs published in the NEJM (2009), demonstrating durable platelet responses in both splenectomized and non-splenectomized patients with chronic ITP. Eltrombopag, an oral TPO-RA, proved its efficacy in the RAISE trial (2011), a phase 3 RCT showing significantly higher platelet responses versus placebo. The EXTEND study confirmed long-term safety and efficacy of eltrombopag over 5+ years. These agents offered a fundamentally new approach: stimulating platelet production rather than suppressing immune destruction.
Follow-up studies, subgroup analyses, and real-world validation
Fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, was approved in 2018 for refractory ITP after the FIT trials demonstrated platelet responses in patients who had failed multiple prior therapies including TPO-RAs. The RITP trial in the UK provided the first large RCT comparing rituximab to standard care, showing higher initial response rates but similar long-term outcomes at 18 months. Avatrombopag, a second oral TPO-RA, expanded treatment options. Sequential treatment strategies emerged, with algorithms guiding clinicians through corticosteroids, TPO-RAs, rituximab, and splenectomy based on response and patient factors. Splenectomy rates declined by >50% in the TPO-RA era, though it remained effective for select patients.
Integration into clinical practice guidelines and recommendations
The ASH 2019 evidence-based guidelines for ITP provided a comprehensive framework incorporating the expanded treatment landscape. Key recommendations included corticosteroids as first-line (preferring short courses over prolonged therapy), TPO-RAs as preferred second-line over rituximab or splenectomy for adults with chronic ITP lasting >3 months, and splenectomy reserved for patients failing medical therapy or preferring a potentially curative approach. The International Consensus Report (2019) aligned with ASH, emphasizing that the goal of treatment is to achieve a safe platelet count to prevent bleeding rather than normalizing counts.
ASH 2019 Guidelines for Immune Thrombocytopenia
First-line: short-course corticosteroids (dexamethasone preferred over prednisone). Second-line: TPO-RAs preferred over rituximab or splenectomy. Splenectomy reserved for ITP >12 months failing medical therapy. Treatment goal: safe platelet count (>20-30 x 10^9/L) rather than normalization.
International Consensus Report on ITP
Sequential approach: corticosteroids first, then TPO-RAs or rituximab. Consider fostamatinib for multi-refractory ITP. Splenectomy effective but should be deferred if possible. Observation appropriate for platelet counts >30 x 10^9/L without bleeding.
Now
Current standard of care and ongoing research directions
ITP management has been transformed from a two-option paradigm (steroids/splenectomy) to a rich multi-agent landscape. TPO-RAs are firmly established as the preferred second-line therapy, with splenectomy rates continuing to decline. Emerging approaches include the neonatal Fc receptor (FcRn) antagonist efgartigimod (under investigation for ITP after success in myasthenia gravis), Bruton tyrosine kinase inhibitors, and complement pathway inhibitors. Key ongoing questions include optimal sequencing of available agents, whether early aggressive treatment prevents chronic ITP, the feasibility of treatment-free remission (some patients achieve sustained responses after TPO-RA discontinuation), and cost-effectiveness of chronic TPO-RA therapy versus one-time splenectomy.
Why are TPO-RAs preferred over splenectomy for second-line ITP treatment?+
TPO-RAs offer comparable response rates (70-80%) without surgical risks, maintain reversibility of treatment decisions, avoid lifelong infection risk from asplenia, and allow reassessment if ITP spontaneously remits. ASH guidelines recommend deferring splenectomy until ITP has persisted >12 months, as many patients achieve remission earlier.
Can patients achieve treatment-free remission on TPO-RAs?+
Approximately 10-30% of patients on long-term TPO-RA therapy can successfully discontinue treatment while maintaining adequate platelet counts. This is more likely in patients with shorter disease duration and those who achieve sustained high platelet counts on low TPO-RA doses. Gradual tapering with close monitoring is recommended.
What platelet count should be the treatment target in ITP?+
Current guidelines target a safe platelet count (>20-30 x 10^9/L in most patients) rather than normalization. Many patients with counts >30 are observed without treatment if asymptomatic. Higher targets (>50) may be appropriate for patients with active bleeding, those requiring surgery, or patients on anticoagulation.
